Patent for lung disease treatment
Europe, Russia and Australia approved a patent for Israeli biotech Kamada’s nebulizer that delivers its Alpha1-Proteinase Inhibitor–Human (AAT) treatment for lung disease. AAT also treats Type 1 diabetes and immune system diseases. Its USA brand name is Glassia.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink